Seattle Children's Hospital/University of Washington School of Medicine
Seattle, WA, United States
Kristen Hayward is an Associate Professor in the Department of Pediatrics, Division of Rheumatology at Seattle Children's Hospital and UW School of Medicine. In additon to her clinical work, Dr Hayward is an active member of the UWSOM Foundations Curriculum where she Co-Leads the Immunology& Microbiology Course for first year medical students and is the Content Lead for Rheumatology for the curriculum. She also serves as the Associate Program Director for the Pediatric Rheumatology Program at SCH. Dr Hayward's scholarly interests include utilizing quality improvement frameworks to assess medical education curriculum and the role of mentorship networks in professional growth.
Sunday, November 12, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): AbbVie/Abbott: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Terminated, August 31, 2021); CIGNA/Express Scripts: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Terminated, August 31, 2021); Merck/MSD: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Terminated, August 31, 2021); Pfizer: Grant/Research Support (Ongoing), Grant/Research Support (Ongoing); Teva: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Terminated, August 31, 2021)
Novel Ideas for Pediatric Rheumatology Training Options
Monday, November 13, 2023
8:00 AM – 8:15 AM PT
Disclosure(s): AbbVie/Abbott: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Terminated, August 31, 2021); CIGNA/Express Scripts: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Terminated, August 31, 2021); Merck/MSD: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Terminated, August 31, 2021); Pfizer: Grant/Research Support (Ongoing), Grant/Research Support (Ongoing); Teva: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Terminated, August 31, 2021)
